Subcutaneous · GLP-1 / glucagon / FGF21 triple
DR10624
4 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
4
Active
2
Recruiting
0
Completed
2
Sites
39
Countries
3
Endpoints
80
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06555640A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia | DR10624 Dyslipidemia | BMI ≥19 | Ph 2 | Completed | 35 | Jun 2025 | — | |
| NCT07024212Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects | DR10624 MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 25-40 | Ph 2 | Active, not recruiting | 4 | May 2026 | — | |
| NCT05378893A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624 | DR10624 Dyslipidemia, Healthy volunteers, Obesity / overweight | BMI 18-32 | Ph 1 | Completed | 1 | Oct 2024 | — | |
| NCT07050134A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque | DR10624 Cardiovascular disease, Dyslipidemia | BMI ≥24 | Not applicable | By invitation | 1 | May 2026 | 7 |